Oral use of interferon

Journal of Interferon and Cytokine Research

Volumn 19, Issue 8, 1999, Pages 853-857

  Cummins, Joseph M ^a   Beilharz, Manfred W ^b   Krakowka, Steven ^c  

^a Amarillo Biosciences Inc   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; DOSE RESPONSE; DRUG EFFECT; HEPATITIS B; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MEASLES; MOUTH CAVITY; MULTIPLE SCLEROSIS; NONHUMAN; NOSE CAVITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERONS; TREATMENT OUTCOME;

ANIMALIA;

EID: 0032819413     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313352     Document Type: Review

References (103)

1. SCHAFER, T.W., LIEBERMAN, M., COHEN, M., and CAME, P.E. (1972). Interferon administered orally: protection of neonatal mice from lethal virus challenge. Science 176, 1326-1327.
2. CUMMINS, J.M., and GEORGIADES, J.A. (1993). How it began. Arch. Immunol. Ther. Exp. 41, 169-172.
3. GRESSER, I., BANDU, M.T., BROUTY-BOYE, D., and TOVEY, M. (1974). Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature 251, 543-545.
4. HAVELL, E.A., YIP, Y.K., and VILČEK, J. (1997). Correlation of physiochemical and antigenic properties of human leukocyte interferon sub species. Arch. Virol. 55, 121-129.
5. BABIUK, L.A., and ROUSE, B.T. (1977). Bovine type II interferon: activity in heterotogous cells. Intervirology 8, 250-256.
6. LIN, L.S., WIRANOWSKA-STEWART, M., CHUDZIO, T., and STEWART II, W.E. (1978). Characterization of the heterologous molecules of human interferons: differences in the cross-species antiviral activities of various molecular populations in human leukocyte interferons. J. Gen. Virol. 39, 125-130.
7. TOVEY, M.G., BANDU, M.T., BEGON-LOURS, J., BROUTY-BOYE, D., and GRESSER, I. (1977). Antiviral activity of bovine interferons on primate cells. J. Gen. Virol. 36, 341-344.
8. TOMPKINS, M.D., and CUMMINS, J.M. (1982). Response of feline leukemia virus-induced nonregenerative anemia to oral administration of an interferon-containing preparation. Feline Practice 12, 6-15.
9. CUMMINS, J.M., and HUTCHESON, D.P. (1983). Effect of interferon on feedlot calves. Proc. Am. Assoc. Bovine Pract. 15, 109-115.
10. CUMMINS, J.M., and HUTCHESON, D.P. (1986). Low dosage of interferon to enhance vaccine efficiency in feedlot calves. Proc. Am. Assoc. Bovine Pract. 18, 135-138.
11. STEED, V.P. (1987). Improved survival of four cats infected with feline leukemia virus after oral administration of interferon. Feline Practice 17, 24-30.
12. DIEZ, R.A., PERDEREAU, B., and FALCOFF, E. (1987). From old results to new perspectives: a look at interferon's fate in the body. J. Interferon Res. 7, 553-557.
13. DIEZ, R.A., PERDEREAU, M.C., MARTYRE, J., WIETZERBIN, J., CORNAERT, S., PETER, M., GAUDELET, C., BARBAROUX, C., DORVAL, T., POUILLART, P., GAVCI, L., and FALCOFF, E. (1986). Pharmacokinetics of [123I]-interferon (IFN) alpha-A In: The Biology of the Interleukin System. K. Cantell and H. Schellekens (eds.) Dorcrecht (Netherlands): Martinus Nijhoff, pp. 549-556.
14. CANTELL, K., and PYHALA, L. (1973). Circulating interferon in rabbits after administration of human interferon by different routes. J. Gen. Virol. 20, 97-104.
15. GIBSON, D.M., COTLER, S., SPIEGEL, H.E., and COLBURN, W.A. (1985). Pharmacokinetics of recombinant leukocyte A interferon following various routes and modes of administration to the dog. J. Interferon Res. 5, 403-408.
16. WILLS, R.J., SPIEGEL, H., and SOLKE, K.E. (1984). Pharmacokinetics of recombinant alpha A interferon following IV infusion and bolus, IM and PO administration to African green monkeys. J. Interferon Res. 4, 399-409.
17. SER. J. Interferon Res. 12, 411-413.
18. GRESSER, I., and DULL, H.B. (1964). A virus inhibitor in pharyngeal washings from patients with influenza. Proc. Soc. Exp. Biol. Med. 115, 192-195.
19. WADDELL, D.J., WILBUR, J.R., and MERIGAN, T.C. (1968). Interferon production in human mumps infections. Proc. Soc. Exp. Biol. Med. 127, 320-324.
20. CATE, T.R., DOUGLAS, R.G., and COUCH, R.B. (1969). Interferon and resistance to upper respiratory virus illness. Proc. Soc. Exp. Bio. Med. 131, 631-636.
21. SMORODINTSEV, A.A., GVOZDILOVA, D.A., ROMANOV, Y.A., MAKARJEV, G.S., RUDENKO, V.I., AKSENOV, O.A., and ZLYDNIKOV, D.M. (1970). Induction of endogenous interferon by use of standard live vaccines for prevention of respiratory viral infections. Ann. N.Y. Acad. Sci. 173, 811-822.
22. JAO, R.L., WHEELOOK, E.F., and JACKSON, G.G. (1970). Production of interferon in volunteers infected with Asian influenza. J. Infect. Dis. 21, 419-426.
23. ISSACS, D., CLARKE, J.R., TYRELL, D.A.J., WEBSTER, A.D.B., and VALMAN, H.B. (1981). Lancet ii (October 31), 950-952.
24. HILL, D.A., BARON, S., PERKINS, J.C., WORTHINGTON, M., VAN KIRK, J.E., MILLS, J., KAPIKIAN, A.Z., and CHANOCK, R.M. (1972). Evaluation of an interferon inducer in viral respiratory disease. J. Am. Med. Assn. 219, 1179-1184.
25. MERIGAN, T.C., REED, S.E., HALL, T.S., and TYRRELL, D.A.J. (1973). Inhibition of respiratory virus infection by locally applied interferon. Lancet 1, 563-567.
26. GATMAITAN, B.C., STANLEY, E.D., and JACKSON, G.G. (1973). The limited effect of nasal Interferon induced by rhinovirus and a topical chemical inducer on the course of infection. J. Infect. Dis. 127, 401-407.
27. HALL, C.B., DOUGLAS, R.R., SIMONS, R.R., and GEIMAN, J.M. (1978). Interferon production in children with respiratory syncytial, influenza and para-influenza virus infections. J. Pediatrics 93, 28-32.
28. MCINTOSH, K. (1978). Interferon in nasal secretions from infants with viral respiratory tract infections. J. Pediatr. 93, 33-36.
29. DOUGLAS, R.G., and BETTS, R.F. (1974). Effect of induced interferon in experimental rhinovirus infections in volunteers. Infect. Immun. 9, 506-510.
30. ZYGRAICH, N., LOBMANN, M., VASCOBOINIC, E., BERGE, and HUYGELEN, C. (1974). In vivo and in vitro properties of a temperature sensitive mutant of infectious bovine rhinotracheitis virus. Res. Vet. Sci. 16, 328-335.
31. TODD, J.D., VOLENEC, F.J., and PATON, I.M. (1972). Interferon in nasal secretions and sera of calves after intranasal administration of a virulent infectious bovine rhinotracheitis virus: Association of Interferon in nasal secretions with early resistance to challenge with virulent virus. Infect. Immun. 5, 699-706.
32. AHL, R., and STRAUB, O.C. (1971). Die lokale Interferonfildung im Respirations-und Genitaltrakt nach experimenteller Infection mit Rhinotracheitis(IBR-und Blaschenausschlag (IPV)-Virus. Dtsch Tieraerztl Wochenschr 78, 653-655.
33. STRAUB, O.C., and AHL, R. (1976). Lokale interferonbildung, beim rind nach intranasaler infektim mit avirulentem IBR/IPV-virus und deren Wirkung auf eine anschlieffende infection mit maul - und Klauenseuche - virus. Zbl. Vet. Med. 23, 470-482.
34. GERBER, J.D., MARRON, A.E., and KUCERA, C.J. (1978). Local and systemic cellular and antibody immune responses of cattle to infectious bovine rhinotracheitis virus vaccines administered intranasally or intramuscularly. Am. J. Vet. Res. 39, 753-760.
35. SAVAN, M., ANGULO, A.B., and DERBYSHIRE, J.B. (1979). Interferon, antibody responses and protection induced by an intranasal infectious bovine rhinotracheitis vaccine. Can. Vet. J. 20, 207-210.
36. COCKER, F.M., NEWBY, T.J., GASKELL, R.M., EVANS, P.A., GASKELL, C.J., STOKES, C.R., HARBOUR, D.A., and BOURNE, J.F. (1986). Responses of cats to nasal vaccination with a live, modified feline herpesvirus type 1. Res. Vet. Sci. 41, 323-330.
37. CUMMINS, J.M., and ROSENQUIST, B.D. (1980). Protection of calves against rhinovirus infection by nasal secretion interferon induced by infectious bovine rhinotracheitis virus. Am. J. Vet. Res. 41, 161-165.
38. CUMMINS, J.M., and ROSENQUIST, B.D. (1982). Temporary protection of calves against adenovirus infection by nasal secretion interferon induced by infectious bovine rhinotracheitis virus. Am. J. Vet. Res. 43, 955-959.
39. CUMMINS, J.M., and ROSENQUIST, B.D. (1982). Partial protection of calves against parainfluenza-3 virus infection by nasal-secretion interferon induced by infectious bovine rhinotracheitis virus. Am. J. Vet. Res. 43, 1334-1338.
40. CUMMINS, J.M., and ROSENQUIST, B.D. (1979). Leukocyte changes and interferon production in calves injected with hydrocortisone and infected with infectious bovine rhinotracheitis virus. Am. J. Vet. Res. 40, 238-240.
41. CUMMINS, J.M., and ROSENQUIST, B.D. (1977). "The effect of cortisol on interferon production by calves inoculated with infectious bovine rhinotracheitis virus." Thesis, University of Missouri-Columbia.
42. HAFF, R.F., SCHRIVER, P.W., ENGLE, C.G., and STEWART, R.C. (1966). Pathogenesis of influenza in ferrets. J. Immunol. 96, 659-667.
43. GREENBERG, S.B., MAURICE, W.H., and JOHNSON, P.E. (1977). Activity of exogenous interferon in the human nasal mucosa. Texas Reports Biol. and Med. 35, 491-495.
44. FUJIOKA, N., AKAZAWA, R., SAKAMOTO, K., OHASHI, K., and KURIMOTO, M. (1995). Potential application of human interferon-α in microbial infections of the oral cavity. J. Interferon Cytokine Res. 15, 1047-1051.
45. SMITH, J.K., CHI, D.S., KRISHNASWAMY, G., SRIKANTH, S., REYNOLDS, S., and BERK, S.L. (1996). Effect of interferon α on HLA-DR expression by human buccal epithelial cells. Arch. Immunol. Ther Exp. 44, 83-88.
46. OHASHI, K., AKAZAWA, R., and KURIMOTO, M. (1994). Effects of interferon-α on a reduced release of interleukin-8 from latently HIV-l-infected monocytic cell line U937 cells. J. Interferon. Res. 14, 129-132.
47. DAO, T., TAKECUCHI, M., FUKUDA, S., and KURIMOTO, M. (1995). Natural human interferon-α enhances the expression of intercellular adhesion molecule-1, integrin α2 and β1 by a mucosal epithelial cell line. Folia Biologica (Praha) 41, 213-225.
48. TAKAYAMA, S., IWAKI, K., NISHIDA, Y., TANAKA, M., FUJH, M., OHASHI, K., IKEDA, M., and KURIMOTO, M. (1997). Effects of oral-mucosal IFNβ on antibody production in mice with induced tolerance. J. Interferon Cytokine Res. 17, S62.
49. FLEISCHMANN, W.R., FIELDS, E.E., WANG, J.L., HUGHES, T.K., and STANTON, G.J. (1991). Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc. Soc. Exp. Biol. Med. 197, 424-430.
50. FLEISCHMANN, W.R., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferons exert their white blood cell suppression effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.
51. BEILHARZ, M.W., MCDONALD, W., WATSON, M.W., HENG, I., MCGEACHIE, J., and LAWSON, C.M. (1997). Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res. 17, 625-630.
52. NAGAO, Y., YAMASHIRO, K., HARO, N., HORISAWA, Y., KATO, K., and UEMURA, A. (1998). Oral-mucosal administration of murine IFN-α potentiates immune response in mice. J. Interferon Cytokine Res. 18, 661-666.
53. KOREN, S., and FLEISCHMANN, W.R. JR. (1993). Orally administered interferons suppress bone marrow function. Soc. Exp. Biol. Med. 204, 155-164.
54. JOHNSON, H.M., SOOS, J.M., MUJTABA, M.G. (1996). IFN Tau Protects Against Autoimmune Neuropathies Via Induction of IL-10 and TGFβ by CD4 Th2 Cells. Eur. Cytokine Network 7, 3.
55. SOOS, J.M., SCHIFFENBAUER, J., and JOHNSON, H.M. (1996). Method of treatment of autoimmune diseases using interferon-tau. World International Property Organization, International Bureau, Geneva, Switzerland. International Pub. No. WO96/28183.
56. SATOH, Y., KASAMA, K., SATOU, M., and MINAGAWA, T. (1998). Anti-allergic effect of oral and systemic administration of rMuIFN beta in allergic peritonitis model mice. Eur. Cytokine Network 9, 132.
57. MUJTABA, M.G., SOOS, J.M., and JOHNSON, H.M. (1997). CD4 T Suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J. Neuroimmunol. 75, 35-42.
58. SOOS, J.M., MUSTAFA, G., MUJTABA, M.G., SUBRAMANIAM, P.S., STREIT, W.J., and JOHNSON, H.M. (1997). Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. 75, 43-50.
59. DEGRE, M., and BUKHOLM, G. (1995). Orally administered interferon-γ but not tumor necrosis factor-α suppress infection with Salmonella typhimurium in a mouse model. J. Biol. Reg. Hom. Agents 9, 15-20.
60. SATOH, Y., KASAMA, K., SATOU, M., and MINAGAWA, T. (1998). Anti-allergic effect of oral and systemic administration of rMuIFN in allergic peritonitis model mice. Eur. Cytokine Network 9, Abstract 389.
61. BROD, S.A., and BURNS, D.K. (1994). Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44, 1144-1148.
62. BROD, S.A., and KHAN, M. (1994). Oral administration of human or murine type 1 interferons suppresses relapses in chronic relapsing EAE [CR-EAE]. Cytokine 6, 567.
63. KHAN, M., and BROD, S.A. (1994). Oral administration of IFN-α in murine EAE prevents adoptive transfer of EAE. Cytokine 6, 568.
64. BROD, S.A., and KHAN, M. (1995). Activated spleen cells from PO IFNα fed donors cannot passively transfer EAE and inhibit concurrent active induction of EAE in adoptive recipients. J. Interferon Cytokine Res. 15, S81.
65. BROD, S.A., and KHAN, M. (1996). Oral administration of IFN-α is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J. Autoimmunity 9, 11-20.
66. BROD, S.A., FOOTE, B., DARCAN, S., PAPOLLA, M., and NELSON, L. (1997). Oral IFN-α delays IDDM in NOD mice. J. Interferon Cytokine Res. 17, S87.
67. CUMMINS, J.M., TOMPKINS, M.B., OLSEN, R.G., TOMPKINS, W.A., and LEWIS, M.G. (1988). Oral use of human alpha interferon in cats. J. Biol. Resp. Mod. 7, 513-523.
68. GILGER, B.C., ROSE, P.D., DAVIDSON, M.G., ROBERTS, S.W., and MILLER, T. (1999). Low dose oral interferon alpha for the treatment of Keratoconjunctivitis sicca in dogs. J. Interferon Cytokine Res. 19, 901-905.
69. YOUNG, A.S., MARITIM, A.C., KARIIUKI, D.P., STAGG, D.A., WAFULA, J.M., MUTUGI, J.J., CUMMINS, J.M., RICHARDS, A.B., and BURNS, C. (1990). Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitology 101, 201-209.
70. CUMMINS, J.M., HUTCHESON, D.P., CUMMINS, M.J., GEORGIADES, J.A., and RICHARDS, A.B. (1993). Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch. Immunol. Ther. Exp. 41, 193-197.
71. GEORGIADES, J.A. (1993). Effect of low dose natural human interferon alpha given into the oral cavity on the recovery time and death loss in feedlot hospital pen cattle: a field study. Arch. Immunol. Ther. Exp. 41, 205-207.
72. MOORE, B.R., KRAKOWKA, S., CUMMINS, J.M., and ROBERTSON, J.T. (1996). Changes in airway inflammatory cell populations in standardbred racehorses after interferon-alpha administration. Vet. Immunol. Immunopathol. 49, 347-358.
73. LECCE, J.G., CUMMINS, J.M., and RICHARDS, A.B. (1990). Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Mol. Biother. 2, 211-216.
74. CUMMINS, J.M., MOCK, R.E., SHIVE, B.W., KRAKOWKA, S., RICHARDS, A.B., and HUTCHESON, D.P. (1995). Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet. Immunol. Immunopath. 45, 355-360.
75. YOSHINO, S. (1995). The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats. Exp. Mol. Pathol. 62, 123-130.
76. BROD, S.A., SCOTT, M., BURNS, D.K., and PHILLIPS, J.T. (1995). Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J. Interferon Cytokine Res. 15, 115-122.
77. YOSHINO, S. (1996). Effects of oral administration of type I interferon on adjuvant arthritis in rats. Comp. Immunol. Micro. Infect. Dis. 19, 133-138.
78. NELSON, P.A., AKSELBAND, Y., DEARBORN, S.M., ALSABBAGH, A., TIAN, Z.J., GONNELLA, P.A., ZAMUIL, S.S., YOUHAI, C., and WEINER, H.L. (1996). Effect of oral beta interferon on subsequent immune responsiveness. Ann. N.Y. Acad. Sci. 778, 145-155.
79. SATOH, Y., KASAMA, K., MIYUKI, S., KUWABARA, M., YANAI, A. and MINAGAWA, T. (1997). Induction of tissue 2′5′ AS and suppression of delayed type of asthma reaction by oral administration of IFN-β in guinea pig asthma model. J. Interferon Cytokine Res. 17, S96.
80. HUTCHINSON, V., and CUMMINS, I.M. (1987). Low-dose oral interferon in patient with AIDS. Lancet ii (December 26), 1530-1531.
81. KOECH, D.K., OBEL, A.O., MINOWADA, J., HUTCHINSON, V.A., and CUMMINS, J.M. (1990). Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1). Mol. Biother. 2, 91-95.
82. JORDAN, W.C. (1994). Three open-label studies of oral interferon alpha in the treatment of HIV disease. J. Natl. Med. Assoc. 86, 257-262.
83. KATABIRA, E., SEWANKAMBO, N., MUGERWA, R., KATAAHA, P., NAAMARA, W., and KARAM, M. (1993). Low-dose oral interferon alpha in the management of symptomatic HIV-I infection. IXth International Conference on AIDS, Berlin 1, 478.
84. BROD, S.A., KERMAN, R.H., NELSON, L.D., MARSHALL, G.D., HENNINGER, E.M., KHAN, M., JIN, R., and WOLINSKY, J.S. (1997). Ingested IFNα has biological effects in humans with relapsing-remining multiple sclerosis. Multiple Sclerosis 3, 1-7.
85. SHIOZAWA, S., TANAKA, Y., and SHIOZAWA, K. (1998). Single-blinded controlled trial of low-dose oral interferon-α for the treatment of xerostomia in patients with Sjögren's syndrome. J. Interferon Cytokine Res. 18, 255-262.
86. BALCERSKA, A., BOHDAN, Z., DROZYNSKA, E., KOZIELSKA, E., SZARSZEWSKI, A., and GEORGIADES, J.A. (1993). Evaluation of the efficacy of human interferon alpha lozenges on the clinical course of childhood neoplasia and in chronic hepatitis B virus infection in patients who were successfully treated for pediatric malignancies. Arch. Immunol. Ther. Exp. 41, 221-228.
87. RATAJCZAK, B. (1993). Observation of the effect of low oral doses of human leukocytic interferon alpha in children with chronic HBV infection and impaired immune response. Arch. Immunol. Ther. Exp. 41, 237-240.
88. ERICSSON, A.D., and CUMMINS, J.M. (1991). Clinical studies of neuromuscular disease. Raum Zeit 2, 26-32.
89. ERICSSON, A.D., and ENGLE, A.C. III. (1991). Clinical studies phase II: polymyositis, Raum Zeit 2, 10-14.
90. HUTCHINSON, V.A., ANGENEND, J.L., MOK, W.L., CUMMINS, J.M., and RICHARDS, A.B. (1990). Chronic recurrent aphthous stomatitis: oral treatment with low-dose interferon alpha. Mol. Biother. 2, 160-164.
91. HUTCHINSON, V.A., MOK, W.L., ANGENEND, J.L., CUMMINS, J.M., and RICHARDS, A.B. (1990). Chronic major aphthous stomatitis: oral treatment with low-dose α-interferon. Mol. Biother. 2, 217-220.
92. LEVEQUE, F., AL-SARRAF, M., KISH, J., CUMMINS, M., and RICHARDS, A. (1998). Low dose oral human Interferon alpha (HuIFNα) to treat mucositis induced by chemotherapy. AACR Annual Meeting, New Orleans, LA, abstract, March 28-April.
93. LECCIONES, J.A., ABEJAR, N.J., DIMAANO, E.E., BARTOLOME, R., CINCO, S., MARIANO, N., YERRO, M.E., COBAR, S., and FUGGAN, B. (1998). A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-α-n1 (Ins) in pediatric patients with measles. J. Interferon Cytokine Res. 18, 647-652.
94. HULTON, M.R., LEVINE, D.L., and FREEDMAN, L.S. (1992). Randomized, placebo-controlled, double-blind study of low-dose oral interferon-α in HIV-1 antibody positive patients. J. Acq. Immune Def. Syn. 5, 1084-1090.
95. KAISER, G., JAEGER, H., BIRKMANN, J., POPPINGER, I., CUMMINS, J.M., and GALLMEIER, W.M. (1992). Low-dose oral natural human interferon-α in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS 6, 563-569.
96. SPERBER, S.J., GOCKE, D.J., HABERZETTL, C.A., and PESTKA, S. (1993). Low-dose oral recombinant interferon-αA in patients with HIV-1 infection: a blinded pilot study. AIDS 7, 693-697.
97. DHINGRA, K., DUVIC, M., HYMES, S., MCLAUGHLIN, P., ROTHBERG, J., and GUTTERMAN, J.U. (1993). A phase-I clinical study of low-dose oral interferon-α. J. Immunotherapy 14, 51-55.
98. TOVEY, M.G. (1997). Stimulation of host defense mechanisms against viral challenges. World International Property Organization, Internal Bureau, Geneva, Switzerland. International Pub. No. WO97/41883.
99. TOVEY, M.G. (1997). Method of treatment. World International Property Organization. Internal Bureau, Geneva, Switzerland. International Pub. No. WO97/41884.
100. TOVEY, M.G. (1997). Stimulation of host defense mechanisms against tumors. World International Property Organization, Internal Bureau, Geneva, Switzerland. International Pub. No. WO97/41886.
101. ROLLWAGEN, P.M., LI, Y.Y., PACHECO, N.D., and NEILSEN, T.B. (1996). Systemic bacteraemia following haemorrhagic shock in mice: alleviation with oral interleukin 6. Cytokine 8, 121-129.
102. ROLLWAGEN, P.M., and BAQAR. (1996). Oral cytokine administration. Immunol. Today 17, 548-550.
103. GEORGIADES, J.A., and FLEISCHMANN, W.R. (1996). Oral application of cytokines. Biotherapy 8, 205-212.